
|Articles|June 1, 2003
Moxifloxacin gains FDA approval
Author(s)Lynda Charters
Dallas-Moxifloxacin ophthalmic solution (Vigamox 0.5%, Alcon Laboratories) was approved by the FDA on April 16 for the treatment of bacterial conjunctivitis, following a 6-month review of the drug.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Spotlight on women's health: Understanding thyroid eye disease
2
FDA extends Aldeyra's reproxalap PDUFA after requesting additional clinical study report
3
NCX 470 advances toward US, China NDA submissions for NCX 470
4
Aviceda Therapeutics reports positive phase 2b SIGLEC results for AVD-104 in geographic atrophy
5








































